Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

October 12, 2017: By Jon Swedien

1 Ophthalmic NewsAzura Ophthalmics has completed a $16 million Series B funding round that will enable it to further develop its dry eye disease treatment candidates, the Israeli company announced Oct. 10.

Azura is developing a portfolio of compounds in combination with a novel drug delivery platform designed to treat meibomian gland dysfunction (MGD), the leading cause of dry eye disease, the company said.

The firm also is preparing for a Phase IIa trial of a drug therapy that has shown efficacy in an initial clinical proof of concept study.

The round was led by a syndicate of OrbiMed, TPG Biotech, and Brandon Capital’s Medical Research Commercialisation Fund, with participation from an existing investor, Ganot Capital.

The company also announced Oct. 10 that Anat Naschitz of OrbiMed, Heather Preston of TPG Biotech, and Chris Nave of Brandon Capital will join the company’s board of directors.

The board also includes Guy Katsav of Ganot Capital, Azura CEO Marc Gleeson, and Yair Alster, MD, Azura’s founder and chief technology officer.

Alster previously co-founded several companies, including Forsight Vision 4 (sold to Roche-Genentech), Forsight Vision 5 (sold to Allergan), and Notal Vision, a commercial stage company.

Gleeson spent 14 years at Allergan as vice president of global marketing for ophthalmology, and then he joined Oculeve.

Azura has also named Charles Bosworth, formerly of Allergan, as its chief medical officer.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023